3,7-dimethyl-indole-2-carboxylic acid ethyl ester | 106270-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3,7-dimethyl-indole-2-carboxylic acid ethyl ester
• 英文别名: 3,7-Dimethyl-indol-2-carbonsaeure-aethylester；ethyl 3,7-dimethyl-1H-indole-2-carboxylate
• CAS: 106270-00-2
• 化学式: C₁₃H₁₅NO₂
• 分子量: 217.268
• InChiKey: HPYDILCDUTXQFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,7-dimethyl-indole-2-carboxylic acid ethyl ester 在 lithium aluminium tetrahydride 、 乙酸乙酯 作用下， 以 四氢呋喃 为溶剂， 以30%的产率得到(3,7-dimethyl-1H-indol-2-yl)methanol
  参考文献：
  名称：

  WO2007/53131

  摘要：

  公开号：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 硫酸 作用下， 生成 3,7-dimethyl-indole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  The Fischer Indole Synthesis. V. 2-Carbethoxy-4,7-dimethylindole from Ethyl Pyruvate 2,6-Dimethylphenylhydrazone¹

  摘要：

  DOI：

  10.1021/ja01578a035

文献信息

• Piperazine derivatives
  申请人：——

  公开号：US20020169163A1

  公开（公告）日：2002-11-14

  Piperazine derivatives, as well as pharmaceutically acceptable salts, solvates and esters thereof, can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea.

  哌嗪衍生物以及其中医药可接受的盐、溶剂合物和酯，可用于制药制剂的形式，用于治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠疾病、尿崩症、2型糖尿病、肥胖和睡眠呼吸暂停。
• SPIRO-PIPERIDINE DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20080139553A1

  公开（公告）日：2008-06-12

  The present invention is concerned with novel indol-2-yl-carbonyl-spiro-piperidine derivatives as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety, depressive disorders and other diseases. The compounds of present invention are represented by the general formula (I) wherein R 1 to R 1 , X and Y are as defined in the specification.

  本发明涉及作为V1a受体拮抗剂的新型吲哚-2-基-羰基-螺环哌啶衍生物，其制备方法，含有它们的药物组合物以及它们用于治疗焦虑、抑郁症和其他疾病的用途。本发明的化合物由通式（I）表示，其中R1至R1、X和Y如规范中所定义。
• Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles
  申请人：——

  公开号：US20020035110A1

  公开（公告）日：2002-03-21

  The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a] indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R 1 to R 8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.

  本发明涉及1,2,3,4,10,10a,-六氢吡唑[1,2-a]吲哚衍生物以及药用可接受的盐、溶剂合物和酯，其中R1至R8具有如权利要求1中所述的意义，用于以药物制剂的形式治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠疾病、尿崩症、肥胖和睡眠呼吸暂停。
• INDOLES
  申请人：Bissantz Caterina

  公开号：US20080139549A1

  公开（公告）日：2008-06-12

  The present invention is concerned with novel indol-2-yl-carbonyl-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of anxiety and depressive disorders and other diseases. Present invention is concerned with compounds of the general formula (I) wherein R 1 to R 6 , R 8 to R 14 , R 12′ , R 13′ , X and Y are as defined in the specification.

  本发明涉及作为V1a受体拮抗剂的新型吲哚-2-基-羰基-哌啶衍生物，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物在预防和/或治疗焦虑和抑郁症等疾病方面具有用途。本发明涉及通式(I)的化合物，其中R1至R6，R8至R14，R12′，R13′，X和Y如规范中所定义。
• [EN] PIPERAZINE DERIVATIVES<br/>[FR] DERIVES DE LA PIPERAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002010169A1

  公开（公告）日：2002-02-07

  The present invention refers to chemical compounds of formula (I) as well as pharmaceutically usable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1. They can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnoea.

  本发明涉及化学式（I）的化合物，以及其可用于制药的盐，溶剂合物和酯，其中R1至R8具有权利要求1中给出的意义。它们可以用于制药制剂的形式，用于治疗或预防中枢神经系统的疾病，中枢神经系统的损伤，心血管疾病，胃肠疾病，尿崩症，肥胖症和睡眠呼吸暂停。